Bioalliance PharmaAct Nom. Cat-P Aktie
| 0,19EUR | 0,00EUR | -1,37% |
WKN: A0HMXA / ISIN: FR0010095596
Personal
| 2021 | 2022 | 2023 | 2024 | 2025 | |
|---|---|---|---|---|---|
| Personal am Ende des Jahres | 24 | 35 | 35 | 35 | 0 |
| Umsatz pro Mitarbeiter in Mio. EUR | 0,17 | 0,04 | 0,05 | 0,05 | 0,00 |
Bilanz (in Mio. EUR) - Aktiva
| 2021 | 2022 | 2023 | 2024 | 2025 | |
|---|---|---|---|---|---|
| Summe Umlaufvermögen | 30 | 21 | 13 | 5 | 5 |
| Summe Anlagevermögen | 23 | 23 | 22 | 13 | 10 |
| Summe Aktiva | 53 | 43 | 35 | 18 | 15 |
Bilanz (in Mio. EUR) - Passiva
| 2021 | 2022 | 2023 | 2024 | 2025 | |
|---|---|---|---|---|---|
| Summe Fremdkapital | 20 | 21 | 20 | 26 | 13 |
| Summe Eigenkapital | 33 | 22 | 15 | -8 | 2 |
| Summe Passiva | 53 | 43 | 35 | 18 | 15 |
Adresse
| 49, blvd. du Général Martial Valin, 75015 Paris | |
| Telefon | +33 (1) 70-38-33-99 |
| Internet | http://www.valeriotx.com |
Management
|
Bryan Giraudo
Independent Director |
|
Hui Ping Jiang
Chief Regulatory Officer |
|
Jacques Mallet
Independent Director |
|
Jean Nicolas Trebouta
Independent Director |
|
Joseph Donahue
Executive Director-Clinical Operations |
|
Joyce Carey
Chief Financial Officer |
|
Julien Miara
Chairman & Chief Executive Officer |
|
Khalil Barrage
Director |
|
Laura Sierra
Head-Clinical Research |
|
Philippe M. Maitre
Head-Business Development & US Division |
|
Robert L Coleman
Independent Director |
|
Robin Sutherland
Vice President & Head-Global Human Resources |
|
Shefali Agarwal
President |
|
Valérie Leroy
Director-Investor Relations & Communications |
ETF-Sparplan
Oskar ist der einfache und intelligente ETF-Sparplan. Er übernimmt die ETF-Auswahl, ist steuersmart, transparent und kostengünstig.